These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7387177)

  • 21. Topical application of potent glucocorticoids augments epidermal beta-adrenergic adenylate cyclase response in vivo.
    Kajita S; Iizuka H; Hirokawa M; Tsutsui M; Mizumoto T
    Acta Derm Venereol; 1986; 66(6):491-6. PubMed ID: 2433868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diflucortolone valerate (Nerisona): a comparative vasoconstriction test in artificially induced hyperemia of the skin.
    Reckers R; Wendt H
    Clin Ther; 1980; 3(3):190-3. PubMed ID: 7459929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of dermal atrophy induced by topical steroids using a radiographic technique.
    James MP; Black MM; Sparkes CG
    Br J Dermatol; 1977 Mar; 96(3):303-5. PubMed ID: 322693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clobetasone butyrate eye drops. Effect on ocular inflammation and intraocular pressure.
    Williamson J; Eilon LA; Walker SR
    Trans Ophthalmol Soc U K (1962); 1981; 101(1):27-9. PubMed ID: 6764318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin.
    Ashworth J; Booker J; Breathnach SM
    Br J Dermatol; 1988 Apr; 118(4):457-69. PubMed ID: 3288268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical retinoic acid does not alter the vasoconstrictive properties of topical corticosteroids in humans.
    Schmied C; Saurat JH
    Dermatologica; 1991; 182(2):107-11. PubMed ID: 2050230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis.
    Parneix-Spake A; Goustas P; Green R
    J Dermatolog Treat; 2001 Dec; 12(4):191-7. PubMed ID: 12241627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assay of topical corticosteroids. Efficacy of suppression of experimental Rhus dermatitis in humans.
    Kaidbey KH; Kligman AM
    Arch Dermatol; 1976 Jun; 112(6):808-13. PubMed ID: 133636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical stability of fluocinolone acetonide ointment and fluocinonide cream diluted in emollient bases.
    Barnes AR; Chapman SB; Irwin WJ
    J Clin Pharm Ther; 1995 Oct; 20(5):265-9. PubMed ID: 8576293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranking of the antipsoriatic effect of various topical corticosteroids applied under a hydrocolloid dressing--skin-thickness, blood-flow and colour measurements compared to clinical assessments.
    Broby-Johansen U; Karlsmark T; Petersen LJ; Serup J
    Clin Exp Dermatol; 1990 Sep; 15(5):343-8. PubMed ID: 2225536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hydrocortisone-17-butyrate, hydrocortisone, and clobetasol-17-propionate on prolyl hydroxylase activity in human skin.
    Oikarinen A; Hannuksela M
    Arch Dermatol Res; 1980; 267(1):79-82. PubMed ID: 6247982
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
    Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
    Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parallel intraindividual evaluation of the vasoconstrictory action and the anti-allergic activity of topical corticosteroids.
    Seidenari S; Di Nardo A; Mantovani L; Giannetti A
    Exp Dermatol; 1997 Apr; 6(2):75-80. PubMed ID: 9209888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of glucocorticosteroids on primary human skin fibroblasts. II. Effects on total protein and collagen biosynthesis by confluent cell cultures.
    Ponec M; Hasper I; Vianden GD; Bachra BN
    Arch Dermatol Res (1975); 1977 Aug; 259(2):125-34. PubMed ID: 907362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum.
    Lawrence CM; Shuster S
    Br J Dermatol; 1985 Jul; 113(1):117-22. PubMed ID: 4015968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients preferences for different corticosteroid vehicles are highly variable.
    Felix K; Unrue E; Inyang M; Cardwell LA; Oussedik E; Richardson I; Feldman SR
    J Dermatolog Treat; 2020 Mar; 31(2):147-151. PubMed ID: 29770722
    [No Abstract]   [Full Text] [Related]  

  • 37. Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.
    Munro DD; Wilson L
    Br Med J; 1975 Sep; 3(5984):626-8. PubMed ID: 1164639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
    Cossmann M; Welzel J
    Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
    Korting HC; Vieluf D; Kerscher M
    Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.